Gene therapy for cardiac diseases: methods, challenges, and future directions
Cardiovascular Research · 2024
DOI: 10.1093/cvr/cvae207 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Luca Grisorio und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Pavia, Via Golgi 19, Pavia, 27100, Italy. Hauptthemen laut MEDLINE: Genetic Therapy, Heart Diseases, Genetic Vectors. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 133 Literaturangaben. Gefördert von: National Center for Gene Therapy and Drugs based on RNA Technology, National Recovery and Resilience Plan.
Abstract (Originalsprache)
Gene therapy is advancing at an unprecedented pace, and the recent success of clinical trials reinforces optimism and trust among the scientific community. Recently, the cardiac gene therapy pipeline, which had progressed more slowly than in other fields, has begun to advance, overcoming biological and technical challenges, particularly in treating genetic heart pathologies. The primary rationale behind the focus on monogenic cardiac diseases is the well-defined molecular mechanisms driving their phenotypes, directly linked to the pathogenicity of single genetic mutations. This aspect makes these conditions a remarkable example of ‘genetically druggable’ diseases. Unfortunately, current treatments for these life-threatening disorders are few and often poorly effective, underscoring the need to develop therapies to modulate or correct their molecular substrates. In this review we examine the latest advancements in cardiac gene therapy, discussing the pros and cons of different molecular approaches and delivery vectors, with a focus on their therapeutic application in cardiac inherited diseases. Additionally, we highlight the key factors that may enhance clinical translation, drawing insights from previous trials and the current prospects of cardiac gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Pavia, Via Golgi 19, Pavia, 27100, Italy.
- Molecular Cardiology, IRCCS Istituti Clinici Scientifici Maugeri, Via Maugeri 10, Pavia, 27100, Italy.
- Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.
- Molecular Cardiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), C/ Melchor Fernandez Almagro 3, Madrid, 28029, Spain.
ORCID-Profile: Silvia Giuliana Priori
Förderung
- National Center for Gene Therapy and Drugs based on RNA Technology
- National Recovery and Resilience Plan
Zitieren
APA
Grisorio, L., Bongianino, R., Gianeselli, M., & Priori, S. G. (2024). Gene therapy for cardiac diseases: methods, challenges, and future directions. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae207
Vancouver
Grisorio L, Bongianino R, Gianeselli M, Priori SG. Gene therapy for cardiac diseases: methods, challenges, and future directions. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae207
BibTeX
@article{Grisorio2024,
author = {Grisorio, Luca and Bongianino, Rossana and Gianeselli, Matteo and Priori, Silvia Giuliana},
title = {Gene therapy for cardiac diseases: methods, challenges, and future directions},
journal = {Cardiovascular Research},
year = {2024},
doi = {10.1093/cvr/cvae207}
}
EUVIMED